Asset Acquisition - Asset Acquisition Cost (Details) - USD ($) $ in Thousands		3 Months Ended		6 Months Ended
	Jun. 22, 2023	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Asset Acquisition [Line Items]
Acquired in-process research and development		$ 0	$ 130,486	$ 0	$ 130,486
Cash acquired				$ 0	$ 3,035
Spyre Therapeutics, Inc.
Asset Acquisition [Line Items]
Consideration transferred in Series A Preferred Stock and Common Stock	$ 110,000
Transaction costs incurred by Pre-Merger Spyre	3,200
Fair value of Parapyre Option Obligation assumed by Pre-Merger Spyre	100
Acquired in-process research and development	130,500
Cash acquired	3,000
Assumed liabilities	(20,200)
Total cost to acquire asset	$ 113,300